Mefenamic acid intravaginal - Plethora

Drug Profile

Mefenamic acid intravaginal - Plethora

Alternative Names: M5003; PSD 508

Latest Information Update: 28 May 2014

Price : $50

At a glance

  • Originator Metris Therapeutics
  • Developer Plethora Solutions
  • Class Antipyretics; Fenamates; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dysmenorrhoea

Most Recent Events

  • 25 Feb 2013 Discontinued - Phase-II for Dysmenorrhoea in United Kingdom (Vaginal)
  • 01 May 2012 No development reported - Phase-II for Dysmenorrhoea in United Kingdom (Vaginal)
  • 08 Jun 2010 Phase-II development is ongoing in UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top